C4 Therapeutics, Inc. 8-K

What Happened

• C4 Therapeutics, Inc. (CCCC) filed a Form 8‑K on May 12, 2026 to announce its quarterly financial results and business highlights for the quarter ended March 31, 2026. The company furnished a press release as Exhibit 99.1 and posted a corporate presentation dated May 2026 on its investor website; that presentation is furnished as Exhibit 99.2. The report was signed by Kendra R. Adams, Chief Financial Officer and Treasurer.

Key Details

• Filing date: May 12, 2026 (Form 8‑K).
• Period covered: quarter ended March 31, 2026 (quarterly results/earnings announced).
• Press release: furnished as Exhibit 99.1 to the 8‑K.
• Presentation: posted to https://ir.c4therapeutics.com/events-presentations and furnished as Exhibit 99.2 (Regulation FD disclosure).

Why It Matters

• This 8‑K notifies investors that C4 has released its latest quarterly earnings and business update and has made related investor materials available. The press release and presentation are primary sources for the company’s reported operating and financial results and any business highlights or guidance mentioned therein. Investors should review the furnished press release and presentation on the company’s IR site for the specific financial figures and management commentary.